Literature DB >> 9066535

Effects of different estrogen and progestin regimens on the mechanical properties of rat femur.

M Kasra1, C M Vanin, N J MacLusky, R F Casper, M D Grynpas.   

Abstract

The purpose of this study was to examine the effects of estrogen replacement, in concert with three different progestin regimens, on the mechanical properties of rat femoral cortical bone. Ninety-two 11-month-old female Sprague-Dawley rats were randomly divided into six groups and were treated for a duration of 6 months. Group-1 rats were intact controls, group-2 rats were ovariectomized controls, and groups 3-6 were ovariectomized and given continuous doses of estrogen with 5% estradiol 17B silicone-rubber implants. Groups 4, 5, and 6 were also given different doses of progestin (norethindrone): group 4 received a continuous dose of 3 micrograms per animal per day, group 5 received a cyclic dose of 6 micrograms per animal per day for 14 days of a 28-day cycle, and group 6 received an interrupted dose of 3 micrograms per animal per day for 3 days of a 6-day cycle. Femurs from each group were mechanically tested. Bending stiffness was measured by nondestructive three-point bending tests and maximum torque capacity, by destructive torsion tests. Geometrical properties and apparent density of cortical bone were also measured. The significant differences were: the increases in elastic modulus (measured from the three-point bending stiffness) of group 5 (cyclic norethindrone) compared with those of group 2 (ovariectomized controls) and group 3 (estrogen only); the increases in the size represented by the moment of inertia, the moment of the area, and medial-lateral width of group 2 compared with those of group 5; and the increases in apparent density and decreases in moment of inertia of group 6 (interrupted norethindrone) compared with those of group 2. Cyclic or interrupted treatment of progestin along with continuous treatment of estrogen after ovariectomy likely improves material properties of cortical bone, increases its density, and reduces the size of the bone compared with ovariectomized rats.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066535     DOI: 10.1002/jor.1100150117

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

2.  Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus.

Authors:  Paul E Goss; Shangle Qi; Haiqing Hu; Lalji K Gediya; Puranik Purushottamachar; Abhijit M Godbole; Vincent C O Njar
Journal:  Breast Cancer Res Treat       Date:  2011-08-14       Impact factor: 4.872

Review 3.  Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  M P Curran; A J Wagstaff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents.

Authors:  Joshua Bernick; Yufa Wang; Ian A Sigal; Benjamin A Alman; Cari M Whyne; Diane Nam
Journal:  J Bone Joint Surg Am       Date:  2014-12-03       Impact factor: 5.284

5.  Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength.

Authors:  Marc Grynpas; Stephen Waldman; Douglas Holmyard; David A Bushinsky
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

6.  The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.

Authors:  Paul E Goss; Shangle Qi; Angela M Cheung; Haiqing Hu; Maria Mendes; Kenneth P H Pritzker
Journal:  J Steroid Biochem Mol Biol       Date:  2004-09       Impact factor: 4.292

7.  Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.

Authors:  Laura D Sardone; Richard Renlund; Thomas L Willett; Ivan G Fantus; Marc D Grynpas
Journal:  Diabetes       Date:  2011-10-12       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.